← Leaderboards
Daniel A Pollyea
University Of Colorado Denver
$825,062
Attributed
$1,650,124
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $825.1K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,650,124 · 2
By mechanism
R01$1,650,124 · 2
Top collaborators
- James V Degregori2 shared
- Craig T. Jordan2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Ming-Feng Tsai$3,618,401
- Mary Cm Weiser-Evans$14,403,734
- Aleem Siddiqui$17,154,020
- Tracy L Bale$25,675,397
- Carla L Van Den Berg$1,980,767
Others in their field
Other Rising Stars on “Inhibitor”
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Michael George Natchus · Emory University$10,548,554
- John Alam · Eip Pharma, Inc.$10,411,018
- Kenneth Schultz · Trethera Corporation$8,384,949
Research focus
InhibitorPathway InteractionsDisease ResistanceImproved OutcomeMolecularPathogenesisDesignDisease RemissionGeneticHeterogeneityLeukemia Initiating CellMediatingAzacitidineNewly DiagnosedBcl2 GeneCharacteristicsAcute Myeloid Leukemia CellChemotherapyDrug ResistanceElderlyClinical TrialsGenotypeAcute Myelocytic LeukemiaPharmaceutical Preparations
Grant awards (4)
Targeting mitochondrial calcium to eradicate leukemia-initiating cells$437,432
R01 · FY2025 · CA
IAP inhibition as a therapeutic strategy to target therapy-resistant leukemia initiating cells$387,630
R01 · FY2025 · CA
Targeting mitochondrial calcium to eradicate leukemia-initiating cells$437,432
R01 · FY2024 · CA
IAP inhibition as a therapeutic strategy to target therapy-resistant leukemia initiating cells$387,630
R01 · FY2024 · CA